Additional factor XII (hageman factor) deficiency in hemophilia a and in von willebrand syndrome

1982 ◽  
Vol 60 (6) ◽  
pp. 303-309 ◽  
Author(s):  
M. Barthels ◽  
J. Edel ◽  
B. Liese ◽  
H. E. Karges
Keyword(s):  
Hemophilia A ◽  
Factor Xii ◽  
Hageman Factor ◽  
Factor Deficiency ◽  
Von Willebrand

scholarly journals Factor XII (Hageman Factor) Deficiency: a rare harbinger of life threatening complications

2019 ◽  
Vol 33 ◽  
Author(s):  
Liaqat Ali Chaudhry ◽  
Wael Yasin Mohamed El-Sadek ◽  
Ghazala Aslam Chaudhry ◽  
Feddha Eid Al-Atawi
Keyword(s):  
Factor Xii ◽  
Hageman Factor ◽  
Factor Deficiency ◽  
Life Threatening

Variations of Factor XII Level During Pregnancy in a Woman with Hageman Factor Deficiency

1988 ◽  
Vol 60 (03) ◽  
pp. 526-527 ◽  
Author(s):  
J F Schved ◽  
J C Gris ◽  
S Neveu ◽  
P Mares ◽  
C Sarlat
Keyword(s):  
Factor Xii ◽  
Hageman Factor ◽  
Factor Deficiency

scholarly journals Factor XII (Hageman Factor) Deficiency: A Very Rare Coagulation Disorder

2015 ◽  
Vol 05 (04) ◽  
pp. 39-42 ◽  
Author(s):  
Mohammad Arphan Azaad ◽  
Qiurong Zhang ◽  
Yongping Li
Keyword(s):  
Coagulation Disorder ◽  
Factor Xii ◽  
Hageman Factor ◽  
Factor Deficiency

Combined von Willebrand disease and Hageman factor deficiency

1977 ◽  
Vol 90 (5) ◽  
pp. 779-781 ◽  
Author(s):  
George R. Buchanan ◽  
Daniel M. Green ◽  
Robert I. Handin
Keyword(s):  
Von Willebrand Disease ◽  
Hageman Factor ◽  
Factor Deficiency ◽  
Von Willebrand

scholarly journals RESPONSE OF FACTOR XII TO DDAVP IN PATIENTS WITH HAGEMAN FACTOR DEFICIENCY

1983 ◽  
Vol 55 (4) ◽  
pp. 713-715 ◽  
Author(s):  
G. Gamba ◽  
G. Grignani ◽  
P. Longoni ◽  
E. Ascari
Keyword(s):  
Factor Xii ◽  
Hageman Factor ◽  
Factor Deficiency

Prevalence of factor XII (Hageman factor) deficiency among 426 patients with coronary heart disease awaiting cardiac surgery

1994 ◽  
Vol 5 (5) ◽  
pp. 451-454 ◽  
Author(s):  
Walter-Michael Halbmayer ◽  
Alexander Haushofer ◽  
Johannes Radek ◽  
Renate Schön ◽  
Manfred Deutsch ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Cardiac Surgery ◽  
Heart Disease ◽  
Factor Xii ◽  
Hageman Factor ◽  
Factor Deficiency

Combined von Willebrand Factor Deficiency and Factor XII Deficiency

2000 ◽  
Vol 83 (03) ◽  
pp. 514-516 ◽  
Author(s):  
Klaus Morgenschweis ◽  
Rainer Zotz ◽  
Ulrich Budde ◽  
Rüdiger Scharf ◽  
Irene Bux-Gewehr
Keyword(s):  
Von Willebrand Factor ◽  
Factor Xii ◽  
Factor Xii Deficiency ◽  
Factor Deficiency ◽  
Von Willebrand ◽  
Willebrand Factor

Comparative Study of Intranasal, Subcutaneous and Intravenous Administration of Desamino-D-Arginine Vasopressin (DDAVP)

1986 ◽  
Vol 55 (01) ◽  
pp. 108-111 ◽  
Author(s):  
M Köhler ◽  
P Hellstern ◽  
C Miyashita ◽  
G von Blohn ◽  
E Wenzel
Keyword(s):  
Factor Viii ◽  
Von Willebrand Factor ◽  
Factor Xii ◽  
Additional Advantage ◽  
Mean Values ◽  
Routes Of Administration ◽  
The Mean ◽  
Von Willebrand ◽  
Willebrand Factor ◽  
Factor Antigen

SummaryThis study was performed to evaluate the influence of different routes of administration on the efficacy of DDAVP treatment. Ten healthy volunteers received DDAVP intranasally (i.n.), subcutaneously (s.c.) and intravenously (i.v.) in a randomized cross-over trial. Factor XII and high molecular weight (HMW)-kininogen levels increased only slightly after DDAVP administration. The mean increase of factor VIII: C was 3.1 (i. v.), 2.3 (s. c.), and 1.3 (i.n.) - fold over baseline. Ristocetin cofactor (von Willebrand factor antigen) increased 3.1 (2.5), 2.0 (2.3) and 1.2 (1.2) - fold over baseline mean values after i.v., s.c. and i.n. DDAVP, respectively. The half-disappearance time of factor VIII and von Willebrand factor (vWF) after DDAVP ranged from five (factor VIII: C) to eight hours (vWF). The mean increase of fibrinolytic activity was more pronounced after i.v. DDAVP. The antidiuretic effect was moderate with no apparent differences between the routes of application. This study provides further evidence that both i.v. and s.c. DDAVP administration result in an appropriate and reliable stimulation of haemostasis. An additional advantage of s. c. administration is its suitability for home treatment.

Sign in / Sign up

Export Citation Format

Share Document